Clinigen expands offering with AI for pharmacovigilance
January 27, 2025The global specialist pharmaceutical services company, Clinigen, announced on Monday a strategic partnership with Tepsivo, a pioneering global digital Pharmacovigilance (PV) services provider, in which Clinigen has acquired a minority stake in Tepsivo.
Nihad Hasagic, SVP of Strategic Initiatives at Clinigen, said that this strategic partnership reflects Clinigen’s confidence in Tepsivo’s automated pharmacovigilance platform and its ability to modernise pharmacovigilance services. “Together, we are not only expanding the range of digital PV solutions available to our clients but also paving the way for a future where technology drives more efficient drug development,” Hasagic said.
Tepsivo co-founder Dominik Hodbod said pointed out that Tepsivo was built to redefine pharmacovigilance by integrating digital innovations, including advanced AI, into every aspect of our platform to provide the highest level of compliance at the lowest cost. Hodbod said that, yy partnering with Clinigen, Tepsivo can accelerate its mission to deliver innovative digital PV solutions to a global audience, empowering clients with tools that enable scientists to focus on real science and improve compliance and patient safety.
Merav Edan, SVP of PV, Regulatory Affairs, and Medical Information Operations at Clinigen, added that Tepsivo’s technology allows Clinigen to offer clients an additional truly modern and future-proof approach to pharmacovigilance services. “By combining their innovative platform with Clinigen’s deep expertise in pharmacovigilance, regulatory affairs, and medical information within our Lifecycle Services business unit, we’re equipping clients with the solutions they need to stay ahead in an increasingly complex regulatory landscape,” Edan said.